Filing Flows

Filing Flows › Health Care › Sonoma Pharmaceuticals (SNOA)

Sonoma Pharmaceuticals (SNOA) earnings and revenue breakdown

Latest: Q1 FY27 · 10-Q filed Aug 6, 2026 · Sonoma Pharmaceuticals (SNOA) Q1 FY27 earnings results →

Q1 FY27 Revenue up 60% year over year to $6.4M · 5¢ of every $1 of revenue lost · operating margin -0.6%

Sonoma Pharmaceuticals made $6.4M in Q1 FY27 (+60% Y/Y). Operating margin -0.6%, net loss $330K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 6, 2026.

Revenue$6.4M
Year over year+60%
Operating margin-0.6%
Net earnings−$330K
Operating cash flow−$649K

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $6.4M in Q1 FY27, up 60% year over year and up 15% from the previous quarter.

Gross margin was 40.2%, up 3.8 points from Q1 FY26. Operating costs exceeded revenue by $40K, an operating margin of -0.6%. Operating expenses grew 2% against revenue growth of 60%. The quarter ended with a net loss of $330K, narrower than the previous quarter's $581K loss. Net interest and other expense of $290K was the main reason.

Operating cash flow was −$649K. Non-cash charges added back $32K of depreciation and amortization and $58K of share-based compensation. Working capital and other items used $409K. Capital expenditures of $2K exceeded it, leaving free cash flow of −$651K.

Quarterly history

Sonoma Pharmaceuticals revenue by quarterSonoma Pharmaceuticals revenue by quarter$3.6MQ3 FY25$3.8MQ4 FY25$4.0MQ1 FY26$5.6MQ2 FY26$4.3MQ3 FY26$5.6MQ4 FY26$6.4MQ1 FY27
Sonoma Pharmaceuticals net earnings by quarterSonoma Pharmaceuticals net earnings by quarter−$928KQ3 FY25−$776KQ4 FY25−$1.2MQ1 FY26−$534KQ2 FY26−$819KQ3 FY26−$581KQ4 FY26−$330KQ1 FY27
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q1 FY2710-QAug 6, 2026$6.4M+60%-0.6%−$330K−$649K
Q4 FY2610-KJun 16, 2026$5.6M+48%-6.3%−$581K−$519K
Q3 FY2610-QFeb 10, 2026$4.3M+22%-15.6%−$819K−$764K
Q2 FY2610-QNov 4, 2025$5.6M+57%-6.0%−$534K−$635K
Q1 FY2610-QAug 7, 2025$4.0M+18%-27.3%−$1.2M−$2.0M
Q4 FY2510-KJun 17, 2025$3.8M+9%-17.5%−$776K−$95K
Q3 FY2510-QFeb 5, 2025$3.6M+14%-28.9%−$928K$565K

Charts

Sonoma Pharmaceuticals: revenue growth, year over year and quarter over quarterSonoma Pharmaceuticals: revenue growth, year over year and quarter over quarterY/YQ/Q+14%Q3 FY25+9%+5%Q4 FY25+18%+7%Q1 FY26+57%+40%Q2 FY26+22%-22%Q3 FY26+48%+28%Q4 FY26+60%+15%Q1 FY27
Latest (Q1 FY27): Y/Y +60%, Q/Q +15%.
Sonoma Pharmaceuticals: where the cash came from (+) and went (−), TTM to Q1 FY27Sonoma Pharmaceuticals: where the cash came from (+) and went (−), TTM to Q1 FY27Shares issued$4.0MOperating cash flow−$2.6MCash drawn (+) / kept (−)−$1.7MExchange rates$399KOther financing$277KNet borrowing (+) / repaid (−)−$272KCapital spending−$88K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Sonoma Pharmaceuticals: profit against cash, quarter by quarterSonoma Pharmaceuticals: profit against cash, quarter by quarterNet incomeOperating cash flow−$610K$354KQ2 FY25−$928K$565KQ3 FY25−$776K−$95KQ4 FY25−$1.2M−$2.0MQ1 FY26−$534K−$635KQ2 FY26−$819K−$764KQ3 FY26−$581K−$519KQ4 FY26−$330K−$649KQ1 FY27
Latest (Q1 FY27): Net income −$330K, Operating cash flow −$649K.
Sonoma Pharmaceuticals: diluted shares by fiscal year (split-adjusted)Sonoma Pharmaceuticals: diluted shares by fiscal year (split-adjusted)6MFY210MFY2210MFY231MFY241MFY252MFY26
-71.9% since FY21: buybacks shrank the count; earlier years scaled for the 3-for-1 split before FY25.
Sonoma Pharmaceuticals in its industry: growth against margin (111 companies, SIC 3841)Sonoma Pharmaceuticals in its industry: growth against margin (111 companies, SIC 3841)revenue growth, year over year →↑ operating marginmedian +10%median -9%MDLNMMMSYKBSXBDXBAXSOLVRMDDXCMWSTMMEDPODDGMEDTFXICUIMMSIIARTPENHAETNDMEMBCIRTCATECGKOSOFIXINSPNVCRUFPTATRCBVSAORTPRCTTCMDARAYANGOKIDSSKINLMATHTFLMDXGCERSSIBNTMCISTIMINFUBBNXKMTSOSURANIKDCTHRCELSGHTIRMDXTNTLUNGNPCEPDEXTELACARLLNSRSIMOBIAPYXSSIICVRXCLPTKRMDTLSIPROFSNWVCTSOIDXGUTMDRVPPREMNEPHDRIOVVOSBTCYNXGLMDAIMDNCPMINONE.SRTSSINTIVFNMTCNSPRAURXXAIRLUCDTNONINBSRNXTVTAKUSAQICUVYCOHRGNCNSYPLSEPETVFEMYOSRHCODXOBIORDGLPAVMGUTSSNOA (+60%, -1%)
Surgical & Medical Instruments & Apparatus; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Sonoma Pharmaceuticals

We originally incorporated as Micromed Laboratories, Inc. in 1999 under the laws of the State of California. We changed our name to Oculus Innovative Sciences, Inc. in 2001. In December 2006 we reincorporated under the laws of the State of Delaware, and in December 2016 we changed our name to Sonoma Pharmaceuticals, Inc. Our principal executive offices are located at 5445 Conestoga Court, Suite 150, Boulder, Colorado 80301. We have two active wholly-owned subsidiaries: Oculus Technologies of Mexico, S.A. de C.V., and Sonoma Pharmaceuticals Netherlands, B.V. Our fiscal year end is March 31. Our corporate telephone number is (800) 759-9305. Our websites are www.sonomapharma.com and www.sonomapharma.eu. The websites and any information contained therein or connected thereto is not intended to be incorporated into this report.

In its own words, from its 10-K, filed Jun 16, 2026.

Sonoma Pharmaceuticals against its Surgical & Medical Instruments & Apparatus peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +60% against the peers' median +5%. Operating margin: -0.6% against the peers' median 13.3%.

CompanyQuarterRevenueY/YOp. margin
SNOA Sonoma PharmaceuticalsQ1 FY27$6.4M+60%-0.6%
MDLN MedlineQ3 2026$7.9B+10%6.4%
MMM 3MQ3 2026$6.6B+1%23.7%
SYK StrykerQ3 2026$6.5B+8%15.9%
BSX Boston ScientificQ3 2026$5.1B+1%16.1%
BDX Becton DickinsonQ3 FY26$5.0B+5%13.3%
BAX Baxter InternationalQ3 2026$3.0B+5%7.6%
SOLV SolventumQ3 2026$1.9B-7%3.5%
RMD ResMedQ1 FY27$1.4B+6%32.0%

Source: Sonoma Pharmaceuticals 10-Q on SEC EDGAR · CIK 1367083 · Surgical & Medical Instruments & Apparatus

13F: who owns SNOA and who is buying

Largest holders of SNOA (13F)Largest holders of SNOA (13F)Vanguard Group$69KRenaissance Technologies LLC$50KGeode Capital Management, LLC$33KVanguard Capital Management LLC$23KMcKinley Carter Wealth Services$14KUBS Group AG$10KGlobal Retirement Partners, LLC$3KMorgan Stanley$2KOsaic Holdings$1KBlackRock$139
Funds' net buying of SNOA by quarter (13F)Funds' net buying of SNOA by quarter (13F)$31K2024-09−$28K2024-12$2K2025-03$181K2025-06−$99K2025-09$180K2025-12−$416K2026-03−$40K2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on SNOA

History

Every quarter: Q1 FY27 results · Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results

Compare SNOA with

中文版：Sonoma Pharmaceuticals（SNOA）财报

Español · Français